Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Thompson OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)critical
2961/989 suggested
  • suggested 90 % decrease in confirmed COVID (any severity) but with a very low degree of certainty due to critical risk of bias
Agur unpublished OBSmRNA vaccineuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
-/- no results
    Shemer OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
    		-/- inconclusive
      Accorsi OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
      		-/- no results
        Comparison of 2 Doses vs Unvaccinated by Time Since Vaccination (graphical presentation) : The upper bound of the 95% CI was consistently greater than 1 starting at 3 months after second dose for BNT162b2 and at 6 months after second dose for mRNA-1273
        Thompson -VISIOn Network (omicron) OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
        		-/- suggested
        • suggested 81 % decrease in hospitalization
        • suggested 52 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
        Thompson -VISIOn Network (omicron) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
        		-/- suggested
        • suggested 90 % decrease in hospitalization
        • suggested 82 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
        UKHSA report week 12 (24 March 2022) OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)NA
        		-/- no results
          UKHSA report week 12 (24 March 2022) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 88 % decrease in deaths,deaths (time to event analysis only)
          • suggested 83 % decrease in hospitalization
          Kirsebom (UKHSA) OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 17 % decrease in symptomatic Covid-19
          CDC Mesa County, Colorado OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
          		-/- suggested
          • suggested 78 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
          HEROES-RECOVER (Fowlkes) OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
          		3483/734 suggested
            Martinez-Baz OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)NA
            		-/- suggested
            • suggested 82 % decrease in confirmed COVID (any severity)
            • suggested 95 % decrease in hospitalization,severe COVID-19 occurrence
            • suggested 82 % decrease in symptomatic Covid-19
            Pawlowski OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)NA
            		31069/31069 suggested
              Pawlowski OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)NA
              		-/- inconclusive
                REACT-1 round 13 final report (Elliott, Imperial College London) OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
                		-/- suggested
                • suggested 59 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
                Shah OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
                		-/- suggested
                • suggested 55 % decrease in confirmed COVID (any severity) but with a low degree of certainty due to high risk of bias
                Shibli OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                		-/- safety concern
                • statistically significant 36 % increase in Bell's palsy
                Tande unpublished OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                		-/- no results
                  Mattiuzzi OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                  		-/- suggested
                  • suggested 85 % decrease in confirmed COVID (any severity)
                  • suggested 85 % decrease in hospitalization
                  Lauring OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                  		5728/5962 suggested
                  • suggested 44 % decrease in death or ventilation
                  • suggested 46 % decrease in death or ventilation
                  • suggested 76 % decrease in death or ventilation
                  • suggested 85 % decrease in hospitalization
                  • suggested 85 % decrease in hospitalization
                  • suggested 65 % decrease in hospitalization
                  Lauring OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                  		5728/5962 suggested
                  • suggested 86 % decrease in hospitalization
                  Ontario (Buchan) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                  		-/- suggested
                  • suggested 37 % decrease in confirmed COVID (any severity)
                  Tenforde OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                  		-/- suggested
                  • suggested 82 % decrease in confirmed COVID (any severity)
                  Tenforde OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                  		-/- suggested
                  • suggested 97 % decrease in confirmed COVID (any severity)
                  Butt OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)moderate
                  		54360/54360 suggested
                  • suggested 97 % decrease in confirmed COVID (any severity) with a moderate degree of certainty due to some concern in risk of bias
                  Chung OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                  		53270/270763 suggested
                  • suggested 91 % decrease in symptomatic Covid-19
                  England (Andrews) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                  		581/130867 suggested
                  • suggested 75 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
                  • suggested 71 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
                  Grannis OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
                  		-/- suggested
                  • suggested 82 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
                  Li OBSInactivated virus vaccinecontrolCOVID-19 prophylaxis (excluding children)critical
                  		74/292 suggested
                  • suggested 59 % decrease in confirmed COVID (any severity) but with a very low degree of certainty due to critical risk of bias
                  REACT-SCOT OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)NA
                  		111295/1093449 suggested
                  • suggested 61 % decrease in hospitalization or death
                  Sisonke 2 (booster)
                                      NCT05148845                  		 OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                  		-/- suggested
                  • suggested 85 % decrease in hospitalization
                  VA (Bajema) OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
                  		-/- suggested
                    Aleman DESCmRNA vaccineuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
                    		-/- no results
                      Boyarsky DESCvaccinesuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
                      		-/- no results
                        Boyarsky DESCmRNA vaccineuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
                        		-/- no results

                          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

                           

                          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons